Regeneron Pharmaceuticals enters the back half of June with an unusual split: options traders are rotating away from defensive positioning just as short sellers add exposure for the first time in weeks.
The clearest shift is in options sentiment. The put/call ratio has dropped to 0.86, more than 1.3 standard deviations below its 20-day average of 0.97 — the most call-skewed reading in over a month. That follows a period running from mid-May into early June when the ratio sat above 1.0, touching a 52-week high of 1.13 on May 19. The reversal is sharp. Investors who were paying heavily for downside protection have pivoted toward calls, even as the stock has shed 12% over the past month to close at $614.73.
Short positioning tells a contrasting story. Short interest has climbed roughly 9% on the week to 3.1% of the free float — still a modest level in absolute terms, but the pace of rebuilding is notable. The move puts short interest back near where it traded through most of May, having briefly compressed in late May and early June. The borrow market offers no friction for this rebuild: availability is extraordinarily loose at nearly 9,000%, and cost to borrow runs below 0.5% annualised — making new short positions essentially free to establish. Squeeze risk is negligible at these levels.
The Street remains broadly constructive but has been re-anchoring price targets lower since mid-May. Following a wave of post-earnings revisions, JPMorgan maintained its Overweight rating while cutting the target from $950 to $850. Citigroup went further, downgrading to Neutral and slicing its target from $900 to $700. Leerink Partners also dropped to Market Perform. Most other houses — Canaccord, Piper Sandler, Truist, BMO — kept positive ratings but trimmed targets by 10–18%. The consensus mean now sits around $833, implying roughly 35% upside from current levels, though the direction of recent moves signals the Street is becoming more selective on near-term valuation. The bull case centres on Dupixent's sustained commercial momentum and a forward earnings growth profile that ranks in the 82nd percentile among biotech peers. The bear case rests on Eylea competitive pressure and pipeline disappointments — the LAG-3 failure in melanoma being the most prominent recent setback.
Valuation has compressed meaningfully. The trailing P/E has moved down to 12.4x, off about 3% over the past month, while EV/EBITDA sits at 7.7x — both multiples suggesting the stock is no longer priced for its prior growth premium. Among close peers, AMGN edged up about 1% on the week and GILD added 1.4%, while INCY fell 3.4% — REGN's 0.2% weekly decline puts it roughly in the middle of the peer group, neither leading the recovery nor underperforming materially.
Institutional ownership remains deep and stable. BlackRock holds nearly 9% of shares, with a modest add of 208,000 shares reported through May. JP Morgan Asset Management added 275,000 shares. Co-founder and CEO Leonard Schleifer holds a 2.4% personal stake. Insider transaction activity in recent months has been limited to small director sales — the $19,000 in net director sales logged by Arthur Ryan in early May carries no read-through on corporate confidence. The ORTEX short score of 35.2 ranks in the 64th percentile, reflecting modest but not extreme short positioning.
Q2 earnings are scheduled for July 29. The previous print on April 29 produced a 3.4% one-day decline and a further 1.5% drift over the subsequent five days — a pattern worth noting as the options market shifts from hedging to more directional call exposure heading into the summer.
See the live data behind this article on ORTEX.
Open REGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
